Successful treatment of macrophage activation syndrome in a patient with dermatomyositis by combination with immunosuppressive therapy and plasmapheresis

被引：18

作者：

Kaieda, Shinjiro ^{[1
]}

Yoshida, Naomi ^{[1
]}

Yamashita, Fumiya ^{[1
]}

Okamoto, Masaki ^{[1
]}

Ida, Hiroaki ^{[1
]}

Hoshino, Tomoaki ^{[1
]}

Fukuda, Takaaki ^{[2
]}

机构：

[1] Kurume Univ, Sch Med, Div Respirol Neurol & Rheumatol, Dept Med, Kurume, Fukuoka 8300011, Japan

[2] Kurume Univ, Med Ctr, Ctr Rheumat Dis, Kurume, Fukuoka 8300011, Japan

来源：

MODERN RHEUMATOLOGY | 2015年 / 25卷 / 06期

关键词：

Dermatomyositis; Hypercytokinemia; Macrophage activation syndrome; Plasma exchange; Tacrolimus; REACTIVE HEMOPHAGOCYTIC SYNDROME; JUVENILE IDIOPATHIC ARTHRITIS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; SOLUBLE INTERLEUKIN-2-RECEPTOR; CLINICAL-FEATURES; STILLS-DISEASE; LYMPHOHISTIOCYTOSIS; TACROLIMUS; EFFICACY; CYCLOSPORINE;

D O I：

10.3109/14397595.2013.844402

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Macrophage activation syndrome (MAS), also known as secondary hemophagocytic lymphohistiocytosis, is mediated by cytokine overproduction from excessive activation of T lymphocytes and macrophages. We present a dermatomyositis patient with MAS, caused by hypercytokinemia. The combination of tacrolimus and plasma exchange therapy was effective in this case for treating MAS. This combination therapy is especially useful for MAS refractory to steroids.

引用

页码：962 / 966

页数：5

共 50 条

[41] Macrophage activation syndrome in juvenile dermatomyositis: a case report and a comprehensive review of the literature
Chang, Yong
Shan, Xueyan
Ge, Yongpeng
PEDIATRIC RHEUMATOLOGY, 2023, 21 (01)
[42] Macrophage activation syndrome in the era of biologic therapy
Grom, Alexei A.
Horne, AnnaCarin
De Benedetti, Fabrizio
NATURE REVIEWS RHEUMATOLOGY, 2016, 12 (05) : 259 - 268
[43] Case report: Macrophage activation syndrome in a patient with Kabuki syndrome
Zhang, Jingyuan
Kang, Yuanbo
Xia, Zenan
Chong, Yuming
Long, Xiao
Shen, Min
FRONTIERS IN IMMUNOLOGY, 2024, 15
[44] Macrophage activation syndrome in juvenile dermatomyositis: a case report and a comprehensive review of the literature
Yong Chang
Xueyan Shan
Yongpeng Ge
Pediatric Rheumatology, 21
[45] Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab
Yokota, Shumpei
Itoh, Yasuhiko
Morio, Tomohiro
Sumitomo, Naokata
Daimaru, Kaori
Minota, Seiji
JOURNAL OF RHEUMATOLOGY, 2015, 42 (04) : 712 - 722
[46] Successful re-administration of tocilizumab in a patient with adult-onset Still's disease after improvement of macrophage activation syndrome
Nagasawa, Yuma
Takase-Minegishi, Kaoru
Adachi, Soichiro
Ichikawa, Kento
Nagai, Hideto
Watanabe, Tomoya
Yamaguchi, Yukie
Yoshimi, Ryusuke
Kirino, Yohei
Nakajima, Hideaki
MODERN RHEUMATOLOGY CASE REPORTS, 2025,
[47] Hyperinflammation: On the pathogenesis and treatment of macrophage activation syndrome
Andersson, Ulf
ACTA PAEDIATRICA, 2021, 110 (10) : 2717 - 2722
[48] Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab
Rahaf Baker
Jean W. Liew
Paul D. Simonson
Lori A. Soma
Gordon Starkebaum
Clinical Rheumatology, 2019, 38 : 603 - 608
[49] Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab
Baker, Rahaf
Liew, Jean W.
Simonson, Paul D.
Soma, Lori A.
Starkebaum, Gordon
CLINICAL RHEUMATOLOGY, 2019, 38 (02) : 603 - 608
[50] Macrophage activation syndrome in MDA5 antibody-positive dermatomyositis and COVID-19 infection
Marzieh Keshtkarjahromi
Sumit Chhetri
Amulya Balagani
Umm-ul-Banin B. Tayyab
Christopher J. Haas
BMC Rheumatology, 5

← 1 2 3 4 5 →